Thomas Prebet, MD, Yale School of Medicine, New Haven, CT, discusses the challenge of treating acute myeloid leukemia (AML) patients who are not eligible for intensive chemotherapy. These patients are generally not eligible for transplantation either. The use of BCL-2 inhibitors and targeted therapies can be beneficial. Combining different agents needs to be investigated to maximize results while still upholding the patients’ quality of life. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).